Desvenlafaxine succinate for major depressive disorder

被引:18
|
作者
Sproule, Beth A. [1 ,2 ,3 ]
Hazra, Monica [1 ]
Pollock, Bruce G. [1 ,2 ,4 ]
机构
[1] Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[3] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
[4] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON, Canada
关键词
D O I
10.1358/dot.2008.44.7.1227147
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Desvenlafaxine (O-desmethylvenlafaxine) is the major active metabolite of venlafaxine. Desvenlafaxine succinate is now undergoing active evaluation for its therapeutic efficacy in a variety of disorders, including major depressive disorder, vasomotor symptoms associated with menopause, fibromyalgia and diabetic neuropathy. Desvenlafaxine is a serotonin and norepinephrine reuptake inhibitor (SNRI) with similar activity to its parent compound venlafaxine, and little affinity for other brain targets, including muscarinic, cholinergic, histamine Hi and cc-adrenergic receptors. Desvenlafaxine has linear pharmacokinetics, low protein binding, a half-life of approximately 10 hours and is metabolized primarily via glucuronidation, and to a minor extent through CYP3A4. The desvenlafaxine succinate formulation appears to have good oral bioavailability. Clearance rates are reduced in the elderly, those with severe renal dysfunction and those with moderate to severe hepatic dysfunction, which may require dosage adjustments. Three published clinical trials have shown supportive but mixed results for the efficacy of desvenlafaxine in the treatment of major depressive disorder with daily doses ranging from 100 mg to 400 mg. One published clinical trial has shown mixed results for the efficacy of desvenlafaxine in the treatment of vasomotor symptoms associated with menopause with daily doses ranging from 50 mg to 200 mg. In these four clinical trials, desvenlafaxine was associated with several mild adverse effects, with the most common effect being nausea. Less common, but more serious, adverse effects reported in these trials included hypertension, QTc interval prolongation, exacerbation of ischemic cardiac disease, elevated lipids and elevated liver enzymes. The exact nature of these serious adverse effects, including the prevalence, clinical significance and potential risk factors, still needs to be fully elucidated. Desvenlafaxine has a low propensity for pharmacokinetic-based drug interactions, although it has the same potential for pharmacodynamic interactions as other serotonin-norepinephrine reuptake inhibitors. Desvenlafaxine is currently another treatment option for major depressive disorder. The only identified potential advantage of desvenlafaxine over venlafaxine or other antidepressant agents at this time is the apparently reduced risk for pharmacokinetic drug interactions.
引用
收藏
页码:475 / 487
页数:13
相关论文
共 50 条
  • [1] Desvenlafaxine succinate for the treatment of major depressive disorder
    Lohoff, Falk W.
    Rickels, Karl
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (12) : 2129 - 2136
  • [2] Pharmacotherapy of Major Depressive Disorder: Focus on Desvenlafaxine Succinate
    Trinidad, Antolin C.
    Bregman, Benjamin
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 381 - 385
  • [3] FDA approves desvenlafaxine succinate for treatment of major depressive disorder
    Cunningham, Jaime
    CNS SPECTRUMS, 2008, 13 (05) : 369 - 369
  • [4] Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder
    Kamath, Jayesh
    DeMartinis, Nicholas
    Handratta, Venkatesh
    FUTURE NEUROLOGY, 2007, 2 (04) : 361 - 371
  • [5] Desvenlafaxine succinate versus Placebo for prevention of depressive relapse in adult outpatients with major depressive disorder
    Pitrosky, B.
    Rickels, K.
    Montgomery, S.
    Tourian, K.
    Guelfi, J. D.
    Padmanabhan, S. K.
    Germain, J. M.
    Leurent, C.
    Brisard, C.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2007, 11 (04) : 335 - 336
  • [6] Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder
    Suh, Jee Su
    Minuzzi, Luciano
    Cudney, Lauren E.
    Maich, William
    Eltayebani, Maha
    Soares, Claudio N.
    Frey, Benicio N.
    NEUROREPORT, 2019, 30 (05) : 378 - 382
  • [7] Desvenlafaxine in the treatment of major depressive disorder
    Lourenco, Maria Teresa C.
    Kennedy, Sidney H.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2009, 5 : 127 - 136
  • [8] Desvenlafaxine for the treatment of major depressive disorder
    Kornstein, Susan G.
    McIntyre, Roger S.
    Thase, Michael E.
    Boucher, Matthieu
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1449 - 1463
  • [9] Desvenlafaxine in the treatment of major depressive disorder
    Pae, Chi-Un
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (18) : 2923 - 2928
  • [10] An integrated analysis of the efficacy of desvenlafaxine succinate compared with placebo in the treatment of major depressive disorder
    Thase, M. E.
    Kornstein, S. G.
    Tummala, R.
    Germain, J. M.
    Jiang, Q.
    Ahmed, S.
    Ninan, P. T.
    EUROPEAN PSYCHIATRY, 2008, 23 : S208 - S208